SYCUME® blocks the activation of IGF-1R signaling pathway mediated by IGF-1 and related ligands or agonistic antibodies, reducing the expression of downstream inflammatory factors. This ...
As China's first and the world's second approved IGF-1R antibody drug, SYCUME ® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback